Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sodium chloride + sodium lactate + calcium chloride + magnesium chloride + dextrose monohydrate** is a peritoneal dialysis solution marketed as **DELFLEX** by Fresenius Medical Care for patients with chronic kidney failure undergoing peritoneal dialysis. It is a sterile hypertonic intraperitoneal solution in which dextrose monohydrate serves as the principal osmotic agent, creating an osmotic gradient across the peritoneal membrane to promote ultrafiltration and removal of water and uremic solutes from the blood, while the electrolyte components help maintain dialysate composition and acid-base balance through lactate buffering. The product has been available in multiple dextrose strengths and electrolyte formulations, including low magnesium and low calcium variants, and is used in the management of chronic kidney failure and historically also acute or chronic renal failure in peritoneal dialysis settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + sodium lactate + calcium chloride + magnesium chloride + dextrose monohydrate.